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ABSTRACT
The discovery that extracellular vesicles (EVs) can transfer functional extracellular RNAs (exRNAs)
between cells opened new avenues into the study of EVs in health and disease. Growing interest in
EV RNAs and other forms of exRNA has given rise to research programmes including but not limited to
the Extracellular RNA Communication Consortium (ERCC) of the US National Institutes of Health. In
2017, the International Society for Extracellular Vesicles (ISEV) administered a survey focusing on EVs
and exRNA to canvass-related views and perceived needs of the EV research community. Here, we
report the results of this survey. Overall, respondents emphasized opportunities for technical develop-
ments, unraveling of molecular mechanisms and standardization of methodologies to increase under-
standing of the important roles of exRNAs in the broader context of EV science. In conclusion, although
exRNA biology is a relatively recent emphasis in the EV field, it has driven considerable interest and
resource commitment. The ISEV community looks forward to continuing developments in the science
of exRNA and EVs, but without excluding other important molecular constituents of EVs.
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Introduction
Studies of extracellular vesicles (EVs) and RNA were
united in the mid- to late-2000s by findings that RNA
molecules were incorporated into EVs and thereby trans-
ferred from cell to cell [1-5]. Communication via extra-
cellular RNA (exRNA) was soon accepted as a novel set of
mechanisms to explain the increasingly appreciated para-
crine effects of EVs. Meanwhile, RNA profiling technol-
ogies advanced quickly, allowing comprehensive
characterization from the small amounts of material
often obtained from extracellular samples [6,7].
Coincidence or not, EV research outputs including
patents and publications grew rapidly following the initial
reports of EVs and exRNA [8]. Indeed, the first scientific
workshop of the International Society for Extracellular
Vesicles (ISEV) was dedicated to the topic of RNA and
EVs [9-11]. Since then, ISEV has maintained attention to
this topic [12]. In light of the importance of RNA in EV
research—but also considering numerous unanswered
questions about RNA EV loading, topology, transfer
mechanisms, functionality and more—ISEV adminis-
tered a worldwide survey on EVs and exRNA in 2017.
The goal of this survey was to measure the pulse of the
community on the state of EV and exRNA science.
Methods
An online survey was prepared with input from the ISEV
Board of Officers and other community members,
including program officers of the US National Institutes
of Health (see Appendix 1 for the full list of questions). In
addition to contact information (optional), 10 scientific
questions were posed. Responses were mandatory for
seven questions and optional for three. Five questions
were multiple-choice or ranking, while the others were
free-response text. Several questions also had “other” text
box options. The survey was announced to the ISEV
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email list and through social media outlets (Facebook and
Twitter) and remained open for 15 days. Two email
reminders were sent to the ISEV email list prior to the
deadline. At the close of the survey, data were collected in
a spreadsheet and analyzed.
Results and Discussion
Numbers and geographical distribution
192 responses were received, including 188 unique
responses based on IP addresses. Approximately 14% of
respondents worked in theAsia Pacific region, 51%were in
Europe or Africa and 35% were located in the Americas
(Figure 1).
Maturity of current understanding
Respondents were asked to rank the maturity of cur-
rent understanding of five aspects of EV biology that
could be seen roughly as sequential parts of an “EV life
cycle”: biogenesis, cargo loading, transport/stability,
uptake, functional cargo transfer. Ranking was from 1
(most knowledge) to 5 (least). The rank from most to
least knowledge was biogenesis, transport/stability,
uptake, cargo loading and cargo transfer. The distribu-
tion of votes (Figure 2) indicates diversity of opinion,
but several results stand out. Biogenesis received by far
the most “1” votes (high level of knowledge), nearly as
many as all other categories combined; results also
otherwise skewed towards the high end. Cargo transfer
and cargo loading received the most and second-most
“5” (least knowledge) votes, and these results were
skewed towards low-knowledge scores. Ambivalence
was apparent for the transport and uptake categories,
with most votes in the middle of the range. These
results suggest perceived unmet needs across all topics,
but especially in cargo loading and cargo transfer.
What is responsible for EV function?
Respondents next identified factors they felt were respon-
sible for the reported effects of EVs: lipids, nucleic acids,
proteins, metabolites, EVs as a whole (not any one con-
stituent molecular category), or particles/molecules asso-
ciated with the outside of EVs (but not part of the EVs
themselves). Multiple selections were permitted, and an
Figure 1. Geographical distribution of respondents by ISEV
geographical chapter. The pie chart represents percentage
from each chapter: Asia-Pacific, Europe/Africa and the
Americas.
Figure 2. EV topics about which we know the “most” [1] to the “least” [5]. Respondents were required to rank the five topics from
most [1] to least knowledge [2]. No rank could be used twice. Shown is the percentage of votes obtained by each. As depicted,
biogenesis received the most votes for the best understood topic, while cargo loading and cargo transfer were thought to be least
understood.
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“other” box was included for comments. Only proteins
were picked as the responsible factor by a majority of
respondents (53%, Figure 3). However, not far behind
were “EV as a whole” (47%) and nucleic acids (46%).
Lipids, extra-EV particles and metabolites received fewer
votes (<20% each). Several respondents suggested in
“other” comments that the answer would depend on the
experimental system, or that current knowledge was too
limited to support a conclusion.
Biomarker potential
As categories with biomarker potential, respondents again
selected from the factors in the previous question. Nucleic
acids and proteins were chosen by a majority of respon-
dents (65% and 54%, respectively), while other factors were
not highly rated (Figure 4). There were several “other”
comments, one raising the point that the study of nucleic
acids and protein is simply more advanced than that of
other potential biomarkers.
Has there been a focus on RNA? If so, is it justified?
Most respondents agreed that an emphasis on RNA is
currently evident in EV research. A majority (almost
62%) suggested that this perceived emphasis was justi-
fied, while 21% did not (Figure 5). Around 18% of
respondents felt that there is not a specific emphasis
on RNA in EV research. In numerous additional com-
ments (Appendix 2), respondents observed that the
emphasis on RNA was a recent development relative
to the longer history of the EV field. Others stressed
that proteins and lipids are also likely to contribute to
EV functions, perhaps as much as or more than RNA.
Respondents commonly favored a more holistic view of
EV function, in which RNA, but also proteins, lipids
and the EV package as a whole play functional roles.
Some stated that certain forms of RNA, especially
miRNA, had likely been emphasized due to stability,
ease of detection or advances in detection methodolo-
gies, likening a focus on specific classes of molecules or
types of RNA to “tunnel vision”. However, others
remained enthused by the potential of RNA in EVs.
What are the current needs in the study of EVs and
exRNA?
Four open response questions completed the survey.
Respondents were asked about the major remaining
challenges in EV/exRNA research and what is needed
to overcome them; fundamental mechanisms of
exRNA and EV biology that must be better understood
for the field to flourish; and what standardized proto-
cols or resources are needed. An open comment box
was also available for thoughts not captured in the
earlier parts of the survey. Since the responses to
these questions overlapped partially, we have attempted
to extract broad themes below, but most substantive
answers are included in the supplementary materials.
A broader view of EVs and exRNA
Responses cautioned against placing exclusive emphasis
on specific types of EVs or exRNA. The existence of
multiple subtypes of EVs has become apparent, and
Figure 3. Factor(s) most responsible for observed effects of EVs.
Respondents could select more than one answer. See supple-
mentary material for selected comments.
Figure 4. Factor(s) with the greatest biomarker potential.
Respondents could select more than one answer. See supple-
mentary material for selected comments.
Figure 5. Is the recent emphasis on RNA justified? Only one
answer was permitted. The pie chart represents percentage.
Total numbers for each answer are given.
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RNA is incorporated not only into exosomes. Similarly,
many exRNA molecules are not found in EVs; they are
abundant in ribonucleoproteins and other non-EV par-
ticles. Like DNA, RNA may also associate with the out-
side of EVs, and not be exclusively luminal. As in the
answers to previous questions, several respondents
emphasized the diversity of small exRNA beyond
miRNAs, to include tRNA fragments, Y RNAs, mRNAs
and beyond small RNA to include longer RNAs.
Molecular context was also underlined. For example, if
RNAs are important, what about RNA binding proteins?
Function and stoichiometry: in vitro and in vivo
Numerous respondents contrasted in vitro and in vivo
studies. In vitro findings are informative and suggestive
but must ultimately be placed into the in vivo context.
That is, to what extent are the numbers of EVs or exRNA
molecules used to establish principles in vitro also rele-
vant to whole organisms? Diverse in vivo models are of
course needed to establish disease relevance and study
mechanism. Respondents encouraged more develop-
ment of models conducive to EV and exRNA studies.
Techniques to deal with small amounts, plus single
EV and single molecule studies
The question of sensitivity is inherent in studies of particles
such as EVs,most ofwhich are a small fraction of the size of
a single cell. Many survey respondents highlighted aspects
of sensitivity, asking for better methods to increase EV or
exRNA yield (without compromising purity) and
improved techniques to obtain and analyze EV subsets.
Several answers tied a lack of concordance of some profil-
ing findings to challenges of low-abundance studies:
throughout, researchers must establish the limits of detec-
tion of their techniques, then be mindful of these limits to
avoid overinterpretation of below-the-threshold data. A
repeated emphasis was on the need for single-EV capabil-
ities, which respondents found to be vital for understand-
ing EV subtypes and their functions. These studies will
require ever-increased sensitivity and optimized techni-
ques for reliable detection of single molecules or at least
low numbers of surface antigens (flow-based technologies)
and RNAs (e.g., digital PCR).
Rigor and reproducibility
One of the most pronounced themes of the survey
responses was scientific rigor and reproducibility, includ-
ing standardization. Respondents urged the application
of rigorous and reproducible approaches to each stage of
the EV/exRNA workflow, from pre-analytical factors/
sample collection through EV and RNA isolation and
bioinformatics analysis. The ISEV minimal information
initiative (MISEV) was praised, but updates and addi-
tional efforts were recommended. These might include
biofluids-specific SOPs; a range of standard reference
materials that can be used to assess isolation efficiency
or spike-ins that are appropriate for specific classes of
EVs or RNAs; and normalization procedures specific to
EV and exRNA studies (see also Table 1, selected sug-
gested protocols, resources and approaches). Answers
suggested that some published “EV” studies are not really
about EVs at all, relying on commercial kits or substan-
dard techniques that are not fit for purpose. At the end of
the pipeline, development of new bioinformatics tools
and curated databases was encouraged, with a goal of
more facile and effective integrated data analysis.
Synergy of better mechanistic understanding and
better tools
Many responses referred to stages of the EV “life cycle”
also covered in “Maturity of current understanding, above,
suggesting that improved technologies are needed to
Table 1. Selected suggested protocols, resources and approaches.
Biofluids-specific EV and exRNA isolation protocols, including those for plasma, serum, CSF, milk.
Methods for isolation and quantification of cell- or tissue-specific EVs from biofluids.
Methods for isolation and quantification of EV subtypes.
SOPs to help increase purity of EVs.
Guidelines for handling and studying small-volume samples.
Evidence-based EV storage methods.
Housekeeping genes for EV RNA normalization, perhaps different for different classes of RNA.
More efficient protocols for removal of extra-EV RNA: it is difficult to remove all “outer” RNA even with combined protease/RNase treatments.
Methods to load EVs with specific RNAs.
Better or more direct sensor systems to measure functions of EV/exRNA uptake.
EV flow (nano-flow) guidelines, including for single-EV assays.
A catalog of EV-relevant antibodies that have been used successfully.
Better molecular labelling methods.
Regular updates to existing protocols and guidelines, including MISEV.
Updated nomenclature.
Simple bioinformatics analysis pipelines.
Updates of existing EV databases to exclude studies that are likely contaminated or rank quality of evidence.
Open minds—avoid standardizing too early or too dogmatically.
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develop better mechanistic understanding and vice versa.
RNA loading into EVswas seen as an area with particular
needs, since there is currently a good deal of uncertainty
about specific versus random incorporation of cargomole-
cules into EVs. Greater understanding could lead to new
technologies for incorporation of specific RNA molecules
into EVs generally or into subtypes of EVs. Questions
about EV transfer to recipient cells brought up the need
for better ways to track individual EVs and their clearance;
assess random versus non-random “trafficking” of EVs,
perhaps based on surface markers; and means to track
uptake or fusion. For RNA function, after an EV reaches
the recipient cell, tools are required to visualize or other-
wise track RNAs as they incorporate into functional
machinery of the recipient cell (or are degraded). Overall,
how does one prove that specific RNAs are responsible
for a given effect? In addition to genome editing, the
needed technologies include improved tools to load speci-
ficmolecules into EVs (again), better label RNA inside cells
and vesicles and delete or functionally disable RNAs after
incorporation into EVs.
Let’s get together: from meetings to training and
collaboration
Many respondents mentioned a need for more collabora-
tion, funding, meetings and/or training. Large annual
meetings were found to be important, but some felt that
more regular local meetings are also needed. Funded con-
sortia like the ERCC of the US National Institutes of
Health were said to be useful but needed in other regions.
Several respondents felt that newcomers to the field needed
more assistance and encouragement and should not be
excluded from networks. Some newcomers said that they
had struggled to find collaborators or slots at training
workshops, indicating a need for more training capacity.
Indeed, in answer to a previous question (for which more
than one answer was allowed), 66% of respondents sug-
gested that more international collaboration was needed,
while 62% asked for more national or regional collabora-
tion. 38% indicated a need for both. Only 10% felt that the
current levels of collaboration were appropriate (Figure 6).
Summary
Overall, the respondents to this ISEV survey on EVs
and exRNA echoed the general enthusiasm about the
role of RNAs in EV function. However, they also stated
that much remains to be learned about the mechanisms
of RNA loading, transfer and function in recipient
cells. Furthermore, while the contribution of RNA to
function was disputed by few, there was an evident
desire to place RNA in the total EV context alongside
other bioactive molecules. On the wish-list of the
respondents were improved techniques, standardized
protocols, enhanced exchange of knowledge and more
resources to advance this exciting area of science.
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